| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
AD-mix-α is an inhibitor of the enzyme DNA gyrase, which plays an important role in the regulation of bacterial cell division and DNA replication. It has been shown to be effective against Pseudomonas aeruginosa and other Gram-negative bacteria. It is extensively used in organic synthesis reactions, including hydrogenation, addition, and carbonylation.
|
|---|---|
| ln Vitro |
AD-mix-α is a biochemical reagent that can be utilized in research pertaining to life sciences as an organic substance or biological material.
In vitro, AD-mix-α is used as a biochemical assay reagent for the differentiation and identification of asymmetric carbon atoms in chiral compounds. It is used in various organic synthesis reactions, such as hydrogenation, addition, and carbonylation, to enhance yield and minimize by-products. It has been shown to be effective against Pseudomonas aeruginosa. |
| ln Vivo |
In vivo data for AD-mix-α as a therapeutic agent are not available, as the compound is a mixture of reagents used for in vitro synthesis and analysis. It is not intended for in vivo administration and has no established in vivo pharmacokinetic or pharmacodynamic profile.
|
| Enzyme Assay |
For in vitro chemical synthesis, AD-mix-α is used as a reagent for asymmetric synthesis. Standard protocols involve using the mixture in reactions such as dihydroxylation of alkenes to produce chiral diols. The exact composition and protocol vary depending on the specific application. The mixture contains a chiral ligand (e.g., (DHQ)₂PHAL) and a metal catalyst (e.g., osmium tetroxide) for enantioselective transformations.
|
| Cell Assay |
For in vitro cell-based experiments, AD-mix-α is not typically used directly in cell culture. It is a chemical reagent used for organic synthesis. The compound may be used in the synthesis of chiral compounds that are subsequently tested in cell-based assays.
|
| Animal Protocol |
In vivo animal studies for AD-mix-α are not applicable, as the compound is a mixture of reagents used for in vitro synthesis. No animal studies have been conducted for this compound as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for AD-mix-α are not available, as the compound is not a drug and is not administered to living organisms. It is a mixture of organic compounds and should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
AD-mix-α is a research chemical and should be handled with appropriate laboratory safety precautions. As a mixture of reactive compounds, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications.
|
| Additional Infomation |
AD-mix-α (CAS 153130-59-7) is primarily a research-grade chemical reagent and biochemical assay reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as a reagent for the differentiation and identification of asymmetric carbon atoms in chiral compounds, in asymmetric synthesis reactions, and as a DNA gyrase inhibitor against Gram-negative bacteria.
|
| Exact Mass |
1257.271
|
|---|---|
| CAS # |
153130-59-7
|
| PubChem CID |
171042500
|
| Appearance |
Yellow to orange solid powder
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
80
|
| Complexity |
1310
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC[C@@H]1CN2CC[C@@H]1C[C@@H]2[C@@H](C3=C4C=C(C=CC4=NC=C3)OC)OC5=NN=C(C6=CC=CC=C65)O[C@@H]([C@H]7C[C@@H]8CCN7C[C@@H]8CC)C9=C1C=C(C=CC1=NC=C9)OC.[CH-]=N.[CH-]=N.[CH-]=N.[CH-]=N.[CH-]=N.[CH-]=N.[C](=O)O[O-].[K].[K].[K+].[K][K].[Fe+6]
|
| InChi Key |
FICQHOUZZTVPNO-AHRKCFNPSA-M
|
| InChi Code |
InChI=1S/C48H54N6O4.6CH2N.CHO3.Fe.5K/c1-5-29-27-53-21-17-31(29)23-43(53)45(35-15-19-49-41-13-11-33(55-3)25-39(35)41)57-47-37-9-7-8-10-38(37)48(52-51-47)58-46(44-24-32-18-22-54(44)28-30(32)6-2)36-16-20-50-42-14-12-34(56-4)26-40(36)42;6*1-2;2-1-4-3;;;;;;/h7-16,19-20,25-26,29-32,43-46H,5-6,17-18,21-24,27-28H2,1-4H3;6*1-2H;3H;;;;;;/q;6*-1;;+6;;;;;+1/p-1/t29-,30+,31-,32+,43-,44-,45-,46-;;;;;;;;;;;;;/m1............./s1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 25 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
